✦ LIBER ✦

Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNFα monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: Preliminary results from a double-blind, placebo-controlled trial

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy (PASI 90 and global

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Efficacy and safety results from a phase

✍ B.E. Strober; J.J. Crowley; P.S. Yamauchi; M. Olds; D.A. Williams 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

Efficacy and safety of topical WBI-1001

✍ R. Bissonnette; C. Bolduc; C. Maari; S. Nigen; J.M. Webster; L. Tang; M. Lyle 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

Efficacy and safety of ustekinumab, a hu

✍ Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Y 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 222 KB

Efficacy and safety of ustekinumab, a hu

✍ Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 295 KB

Impact of ustekinumab on health-related

✍ Hidemi NAKAGAWA; Brad SCHENKEL; Mai KATO; Takeshi KATO; Atsuyuki IGARASHI; The J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 317 KB